骨髓源性抑制细胞在肿瘤免疫治疗中的研究进展及与肺癌预后的关系

The research progress of myeloid-derived suppressor cells in tumor immunosuppressive therapy and its relationship with prognosis of lung cancer

免疫治疗是肺癌新兴治疗方法,其疗效受肿瘤免疫微环境(tumor immune microenvironment,TIME)影响。骨髓源性抑制细胞(myeloid-derived suppressor cells,MDSCs)是免疫微环境的主要免疫抑制细胞,在肿瘤的发生、发展、侵袭和转移过程中起关键作用。近年来,探索克服MDSCs的免疫抑制,从而增强抗肿瘤治疗疗效的研究已经成为研究热点。在这篇综述中,我们讨论了靶向MDSCs以及与ICI联合治疗的进展,并总结了MDSCs对肺癌患者预后的影响。

The immunotherapy is a new treatment for lung cancer and its therapeutic efficacy is affected by the tumor immune microenvironment.Myeloid-derived suppressor cells(MDSCs)are the primary immunosuppressive cells in the immune microenvironment and play a key role in the occurrence,development,invasion and metastasis of tumors.In recent years,the research on overcoming the immunosuppression of MDSCs and enhancing the efficacy of anti-tumor therapy has become a hot topic.In this review,we discuss the progress of targeting MDSCs and co-treatment with ICI,and summarize the effects of MDSCs on prognostication in lung cancer patients.